All In Biotech

Drug Trial Radar · NCT06810050

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

Safety and Effectiveness of CGB-500 Topical Ointment With 0.5% and 1% Tofacitinib for the Treatment of Atopic Dermatitis: A Randomized, Dose-Ranging, Vehicle-Controlled, Double-Blind Trial

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Dec 18, 2024

Primary completion

Aug 30, 2025

Study completion Oct 30, 2025

Sponsor

Lead sponsor
CAGE Bio Inc.Industry
Sponsor type
Industry
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis. Participants will: Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks. Keep a diary of when they use the product and complete a form about their symptoms including itching.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • CGB-500 with 0.5% tofacitinibDrug

    CGB-500 is a proprietary ointment formulation

  • CGB-500 Ointment with 1% tofacitinibDrug

    CGB-500 is a proprietary ointment formulation

  • Vehicle (placebo)Drug

    placebo ointment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: From enrollment to end of study at 8 weeks
  2. evaluate effectivenessTime frame: From enrollment to end of study at 8 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology Clinical Research Inc.

    Fremont, California

  • Ablon Skin Institute and Research Center

    Manhattan Beach, California

  • TCR Medical Corporation

    San Diego, California

  • Syrentis Clinical Research

    Santa Ana, California

  • USA and International Research Inc.

    Doral, Florida

  • FXM Clinical Research

    Fort Lauderdale, Florida

  • Driven Research

    Gables, Florida

  • FXM Clinical Research Miami, LLC

    Miami, Florida

  • FXM Clinical Research Miramar, LLC

    Miramar, Florida

  • Cordova Research Institute

    Sweetwater, Florida

  • The Indiana Clinical Trials Center, PC

    Plainfield, Indiana

  • Metro Boston Clinical Partners

    Brighton, Massachusetts

  • J&S Studies, Inc.

    New Brighton, Minnesota

  • JDR Dermatology Research

    Las Vegas, Nevada

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • DermResearch

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.